Evaluation of the anti-inflammatory and anti-tumor effect of Ipomoea obscura (L) and its mode of action through the inhibition of proinflammatory cytokines, nitric oxide and COX-2.
Ipomoea obscura (L) is a widely used medicinal plant. In this study, we investigated its anti-inflammatory and anti-tumor effect using in vitro and in vivo models. Methanolic extract of I. obsucra (10 mg/kg b.wt) was given interaperitoneally before inducing inflammation (both acute and chronic) and tumor to mice. I. obscura produced significant inhibition of 55.6%, 42%, and 65% in the paw edema of animals induced by carrageenan, dextran, and formalin respectively. The extract was also a potent inhibitor of lipopolysaccharide (LPS)-induced NO, CRP, and proinflammatory cytokine production via gene expression in peritoneal macrophages. TNF-α production by macrophage culture treated with LPS was found to be significantly inhibited by I. obscura. The extract was 100% toxic at a concentration of 500 µg/mL for both Dalton's lymphoma ascites (DLA) and Ehrlich ascites carcinoma (EAC) cells. The extract was also found to inhibit tumor cell proliferation in a dose and time-dependent manner. It could also inhibit solid tumor development in mice induced with DLA cells and increased life span of mice bearing EAC tumor to 83% and 53.8%, respectively. This anti-inflammatory effect of the extract is assumed to result mainly from the inhibition of some key enzymes and mediators involved in the inflammation and/or cell signaling pathways such as iNOS, COX-2, and proinflammatory cytokines. This anti-inflammatory property might be the reason for its anti-tumor effects.
Hamsa
T P
TP
Department of Immunology, Amala Cancer Research Centre, Amala Nagar, Thrissur, Kerala, 680 555, India.
Kuttan
Girija
G
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology*; D001483:Base Sequence; D002097:C-Reactive Protein / Q000037:antagonists & inhibitors / Q000378:metabolism; D002460:Cell Line; D052246:Cyclooxygenase 2 Inhibitors / Q000302:isolation & purification / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics; D017931:DNA Primers / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D066298:In Vitro Techniques; D007249:Inflammation / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D027741:Ipomoea / Q000737:chemistry*; D008515:Medicine, Ayurvedic; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology; D010946:Plants, Medicinal / Q000737:chemistry*
D000893:Anti-Inflammatory Agents; D000972:Antineoplastic Agents, Phytogenic; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D017931:DNA Primers; D018836:Inflammation Mediators; D010936:Plant Extracts; D009569:Nitric Oxide; D002097:C-Reactive Protein
J Immunol. 1988 Mar 15;140(6):1999-2007
3257994
J Biol Chem. 2001 Aug 24;276(34):32008-15
11410599
Planta Med. 1992 Feb;58(1):19-21
1620738
Biol Pharm Bull. 2004 Dec;27(12):2028-31
15577226
Cancer Res. 1966 Aug;26(8):1787-800
4288553
Cancer Lett. 1995 Jul 20;94(1):79-83
7621448
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
14001233
J Pharmacol Exp Ther. 1969 Mar;166(1):96-103
5776026
Acta Pharmacol Sin. 2004 Apr;25(4):480-4
15066217
Carcinogenesis. 1988 Dec;9(12):2297-304
2847879
Arch Biochem Biophys. 2003 Sep 1;417(1):3-11
12921773
J Nat Med. 2010 Jan;64(1):42-9
19830512
J Exp Med. 1993 Jul 1;178(1):63-72
8315395
Indian J Exp Biol. 2000 Jan;38(1):88-90
11233093
J Ethnopharmacol. 2008 Jun 19;118(1):166-72
18486371
Nat Rev Drug Discov. 2003 Sep;2(9):736-46
12951580
Surv Synth Pathol Res. 1985;4(1):44-68
3895348
J Orthop Res. 2003 Mar;21(2):256-64
12568957
Biochem Pharmacol. 2002 Feb 1;63(3):343-7
11853685
Anal Biochem. 1982 Oct;126(1):131-8
7181105
Science. 1985 Nov 22;230(4728):943-5
3933111
Indian J Exp Biol. 1997 Mar;35(3):236-9
9332168
Cancer Res. 1998 Apr 15;58(8):1723-9
9563490
J Investig Med. 1995 Feb;43(1):58-67
7719760
Pharm Res. 1996 Aug;13(8):1133-44
8865302
Phytochemistry. 2003 Apr;62(8):1257-63
12648548
Cancer Chemother Pharmacol. 1986;17(3):259-63
3742711
Braz J Med Biol Res. 2003 Jan;36(1):105-12
12532233
J Exp Med. 1974 Mar 1;139(3):528-42
4591170
Immunol Lett. 1995 Nov;48(1):59-64
8847093
Lancet. 2001 Feb 17;357(9255):539-45
11229684
J Immunol Methods. 1992 Jul 6;151(1-2):313-5
1629621
Immunopharmacol Immunotoxicol. 2009 Jun;31(2):222-9
18798043
Biochem Pharmacol. 2006 Nov 30;72(11):1605-21
16889756
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5258-65
7777494
Ann Surg. 1995 Mar;221(3):220-35
7717775
Eur J Pharmacol. 2007 Mar 8;558(1-3):185-93
17207792
Cancer Metastasis Rev. 2006 Sep;25(3):481-91
17103050